Article Text

other Versions

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
  1. Freddy Cornillie1,
  2. Stephen B Hanauer2,
  3. Robert H Diamond3,
  4. Jianping Wang4,
  5. Kezhen L Tang4,
  6. Zhenhua Xu5,
  7. Paul Rutgeerts6,
  8. Séverine Vermeire6,7
  1. 1Department of Immunology, Janssen Biologics BV, Leiden, The Netherlands
  2. 2Departments of Gastroenterology, Hepatology, and Nutrition, The University of Chicago Medicine, Chicago, Illinois, USA
  3. 3Medical Group, Janssen Biotech, Inc, Horsham, Pennsylvania, USA
  4. 4Biostatistics and Programming, Janssen Research & Development, LLC, Horsham, Pennsylvania, USA
  5. 5Biologics Clinical Pharmacology, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA
  6. 6Department of Gastroenterology, University Hospital Gasthuisberg, KU Leuven, Belgium
  7. 7National Fund for Scientific Research (FWO), Flanders, Belgium
  1. Correspondence to Dr Freddy Cornillie, Department of Immunology, Janssen Biologics BV, Archimedesweg 29, 2333 CM Leiden, The Netherlands; fcornill{at}


Background Serum infliximab trough levels correlate with efficacy; dose escalation is often beneficial in patients with Crohn's disease who stop responding to infliximab treatment.

Objective To carry out a post hoc analysis of A Crohn's Disease Clinical Trial Evaluating Infliximab in a New Long-term Treatment Regimen I (ACCENT I) to evaluate the association between serum infliximab trough levels and C-reactive protein (CRP) after 14 weeks of induction treatment with durable sustained long-term response (Crohn's Disease Activity Index decrease ≥70 points and reduction ≥25% from baseline).

Design ACCENT I was a multicentre, randomised, placebo-controlled study. Week 14 trough levels and CRP percentage decrease from baseline to week 14 were compared between patients with and without durable sustained response through week 54. Sensitivity and specificity were determined to predict durable sustained response. Receiver operating characteristic (ROC) curves identified optimal cut-off points; logistic regression determined ORs.

Results After induction with 5 mg/kg infliximab, 25% (37/147) and 33% (47/144) of patients sustained week 14 response to infliximab 5 or 10 mg/kg, respectively, administered every 8 weeks without dose escalation, through week 54. Median week 14 trough levels of patients with and without durable sustained response to infliximab 5 mg/kg were 4.0 and 1.9 μg/mL, respectively (p=0.0331). Optimal predictors of durable sustained response to maintenance infliximab 5 mg/kg were week 14 trough level ≥3.5 µg/mL and ≥60% CRP decrease (ORs (95% CI), 3.5 (1.1 to 11.4) and 7.3 (1.4 to 36.7)), respectively, in patients with raised baseline CRP (>8.0 mg/L); area under the ROC curve was 0.75 for both predictors. A ≥3.5 µg/mL week 14 infliximab serum level did not predict durable sustained response to 10 mg/kg maintenance infliximab.

Conclusions Patients with durable sustained response to maintenance infliximab 5 mg/kg had higher postinduction trough levels than patients without durable sustained response. Serum infliximab trough levels ≥3.5 µg/mL and ≥60% CRP decrease were significantly associated with durable sustained response.


Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.